000			02212 a2200589 4500
005			20250517122844.0
264		0	_c20170808
008			201708s 0 0 eng d
022			_a1872-7980
024	7		_a10.1016/j.canlet.2016.10.025 _2doi
040			_aNLM _beng _cNLM
100	1		_aCholewa, Brian D
245	0	0	_aSmall molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. _h[electronic resource]
260			_bCancer letters _c01 2017
300			_a179-187 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aCaspase 3 _xmetabolism
650	0	4	_aCell Cycle Proteins _xantagonists & inhibitors
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCyclin-Dependent Kinase Inhibitor p21 _xmetabolism
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aG2 Phase Cell Cycle Checkpoints _xdrug effects
650	0	4	_aHumans
650	0	4	_aKi-67 Antigen _xmetabolism
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aMice, Nude
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aMutation
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProtein Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aProto-Oncogene Proteins _xantagonists & inhibitors
650	0	4	_aProto-Oncogene Proteins B-raf _xgenetics
650	0	4	_aPteridines _xpharmacology
650	0	4	_aS Phase Cell Cycle Checkpoints _xdrug effects
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aTime Factors
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aTumor Suppressor Protein p53 _xmetabolism
650	0	4	_aXenograft Model Antitumor Assays
650	0	4	_aPolo-Like Kinase 1
700	1		_aNdiaye, Mary A
700	1		_aHuang, Wei
700	1		_aLiu, Xiaoqi
700	1		_aAhmad, Nihal
773	0		_tCancer letters _gvol. 385 _gp. 179-187
856	4	0	_uhttps://doi.org/10.1016/j.canlet.2016.10.025 _zAvailable from publisher's website
999			_c26560429 _d26560429